A Phase 2, Open-Label Study to Investigate the Safety and Efficacy of Faldaprevir and TD 6450 Alone and in Combination With Other Antivirals for 12 Weeks in Treatment-Naive Patients Chronically Infected With Genotype 1 Hepatitis C Virus
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 03 Feb 2017
At a glance
- Drugs Faldaprevir (Primary) ; Ribavirin (Primary) ; TF 6450 (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- Sponsors Trek Therapeutics
- 27 Jan 2017 Planned End Date changed from 1 Jun 2017 to 1 Jul 2017.
- 27 Jan 2017 Planned primary completion date changed from 1 May 2017 to 1 Jul 2017.
- 27 Jan 2017 Status changed from recruiting to active, no longer recruiting.